Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Medicina Personalizada en Prediabetes y Diabetes Tipo 2 Temprana (PREDICT)

30 de septiembre de 2026 actualizado por: Garvan Institute of Medical Research

Personalised Medicine in Prediabetes - Towards Preventing Diabetes in Individuals at Risk

Prediabetes is a common condition in overweight individuals affecting approximately 35% of American adults and 30% of Australian adults. Like diabetes, prediabetes is a serious risk factor for cardiovascular disease, eye, kidney and liver disease, and some types of cancer.

Appropriate blood glucose control is crucial in preventing pre-diabetes complications and onset of diabetes, yet clinical practice, backed by randomised trials, reports that many patients treated with standard dietary guidelines or with the first-line treatment of diabetes patients, metformin, do not improve blood glucose control sufficiently.

The overarching goal of the present project is to improve the efficacy of metformin mono-therapy in pre-diabetes and early type 2 diabetes.

Descripción general del estudio

Descripción detallada

Prediabetes is common in overweight and obese individuals and, as with frank diabetes, it is a risk factor for cardiovascular disease, cognitive dysfunction, fatty liver, kidney, ophthalmic, renal and neuropathic disease, and cancer.

Effective management of dysglycemia in pre-diabetes and diabetes and prevention of diabetes in individuals at risk reduce the risk of organ damage and associated co-morbidities and improves the affected individuals' quality of life.

Metformin, an oral biguanide, is the first-line treatment of newly-diagnosed type 2 diabetes patients, and the pharmacological choice for preventing diabetes in individuals with pre-diabetes. Metformin is an ideal medication to initiate for diabetes prevention, due to its excellent safety profile (lack of hypoglycemia), neutral to marginally beneficial effect on body weight, evidence of cardio-protection, and low cost. However, clinical practice, backed by randomised clinical trials, suggests that metformin mono-therapy fails to achieve glycemic goals in 20-40% of type 2 diabetes patients and to prevent diabetes in approximately 20% of individuals with pre-diabetes.

While the mode of action of metformin is still being investigated, the liver and the gastrointestinal tract are thought to be the main targets responsible for the improvement in glycemia. An increasing body of evidence suggests that the gut microbiota play an important role in obesity, prediabetes and diabetes, and alterations in gut microbial composition have been described in individuals with type 2 diabetes and pre-diabetes. Interestingly, metformin-treated diabetes patients have a "healthier" gut microbial composition compared with treatment-naïve diabetes patients, and changes in gut microbial composition with metformin treatment has been suggested to contribute to the therapeutic effect of the medication.

Randomised, clinical study with parallel assignment and single-masking will be performed in treatment-naïve individuals with pre-diabetes or early type 2 diabetes (diagnosed in the last 6 months) aiming to compare the effect of metformin (extended release [XR]) 1500 mg/d administered with personalized diet (based on the Weizmann Institute Personalized Nutrition Project) or administered with a healthy (low fat) diet.

Tipo de estudio

Intervencionista

Inscripción (Actual)

138

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • New South Wales
      • Sydney, New South Wales, Australia, 2010
        • Garvan Institute of Medical Research

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

20 años a 70 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion criteria:

  • Prediabetes or early-stage type 2 diabetes according to the American Diabetes Association (2019) diagnostic criteria, with HbA1c ≤8.0% (64 mmol/mol).
  • Women of childbearing potential willing to take precautions to avoid pregnancy throughout the study and for 3 months after the end of treatment.
  • Willingness to provide written informed consent and willingness to participate and comply with the study.

Exclusion Criteria:

  • Females planning a pregnancy during the course of the research or 3 months after completion of the research project. Females who breastfeed.
  • Patients with type 1 diabetes, chronically active inflammatory disease, neoplastic disease in the previous 3 years, chronic gastrointestinal disorders, including inflammatory bowel disease or celiac.
  • Liver enzymes ALT and/or AST>3-times normal range limit.
  • Abnormal renal function as measured by (eGFR<45 mL/min/1.73m^2).
  • Individuals with a history of a psychological illness or condition that may interfere with the individual's ability to understand the requirements of the study.
  • Normo-glycaemia.
  • HbA1c>8.0%
  • Cardiovascular event in the previous 6 months.
  • Current or recent (within 24 months) treatment with a glucose lowering medication (i.e. GLP-1 receptor agonist, SGLT2 inhibitor, thiazolidinedione, sulfonylurea, DPP-4 inhibitor or insulin).
  • Current or recent (within 3 months) treatment with metformin.
  • Treatment with an oral steroid.
  • Treatment with antibiotics in the last 3 months.
  • Treatment with immunosuppressive medications.
  • Treatment with medications known to interact with metformin, including cimetidine, vitamin K antagonists and nifedipine.
  • Substance abuse.
  • Participants who had received an investigational new drug within the last 6 months.
  • Participants involved in another clinical study.
  • Participants who actively lose weight.
  • Participants who had a bariatric surgery.
  • Any reason the Investigator believes the participant is not likely to be adherent to the study treatment and protocol, including non-adherence to run-in.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador de placebos: Metformin + Healthy diet

Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet

Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet

Otros nombres:
  • Metformina + Dieta saludable (baja en grasas)
Comparador activo: Metformin + Personalized diet

Metformin (1500 mg/d, Extended Release) + Personalized diet based on an algorithm developed at the Weizmann Institute of Science (Zeevi et al, Cell 2015)

Metformin (1500 mg/d, Extended Release) + Algorithm-based personalized diet

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Mean change in glycated haemoglobin (HbA1C, %) from baseline
Periodo de tiempo: 6 months

Difference in the reduction of HbA1C between the groups

6 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Total daily time of interstitial glucose levels below 7.8 mmol/L (140 mg/dL)
Periodo de tiempo: 6 months

Difference in the time (minutes) per day with interstitial glucose measured below 7.8 mmol/L (140 mg/dL) between the groups

6 months
Glycaemic variability
Periodo de tiempo: 6 months

Difference in the glycaemic variability as derived from CGM between the groups

6 months
Body weight
Periodo de tiempo: 6 months

Difference in the magnitude of weight loss between the groups

6 months
Body fat mass
Periodo de tiempo: 6 months

Difference in body fat mass composition as assessed using dual-energy X-ray absorptiometry (DXA) between the groups

6 months
Abdominal visceral fat volume
Periodo de tiempo: 6 months

Difference in the abdominal visceral fat volume as assessed using DXA between the groups

6 months
Serum low-density lipoprotein (LDL)-cholesterol concentration
Periodo de tiempo: 6 months

Difference in serum LDL-cholesterol between the groups

6 months
Serum high-density lipoprotein (HDL)-cholesterol concentration
Periodo de tiempo: 6 months

Difference in serum HDL-cholesterol concentration between the groups

6 months
Serum triglycerides concentration
Periodo de tiempo: 6 months

Difference in serum triglycerides between the groups

6 months
Blood pressure
Periodo de tiempo: 6 months

Difference in diastolic and systolic blood pressure between the groups

6 months
Liver fat
Periodo de tiempo: 6 months

Difference in liver fat measured by the Fibroscan's controlled attenuation parameter (CAP) function between the groups

6 months

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Gut microbiome (exploratory)
Periodo de tiempo: 6 months

Difference in gut microbiome features between the groups

6 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Dorit Samocha-Bonet, PhD, Garvan Institute of Medical Research
  • Investigador principal: Jerry Greenfield, MD, PhD, Garvan Institute of Medical Research
  • Investigador principal: Eran Elinav, MD, PhD, Weizmann Institute of Science
  • Investigador principal: Eran Segal, PhD, Weizmann Institute of Science

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

5 de junio de 2018

Finalización primaria (Actual)

15 de diciembre de 2023

Finalización del estudio (Actual)

23 de julio de 2024

Fechas de registro del estudio

Enviado por primera vez

5 de junio de 2018

Primero enviado que cumplió con los criterios de control de calidad

5 de junio de 2018

Publicado por primera vez (Actual)

15 de junio de 2018

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

30 de septiembre de 2026

Última verificación

1 de agosto de 2023

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir